Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study

Authors: Ida Laake, Inger K. Larsen, Randi Selmer, Inger Thune, Marit B. Veierød

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Whether excess body weight influences colorectal cancer (CRC) survival is unclear. We studied pre-diagnostic body mass index (BMI) and weight change in relation to CRC-specific mortality among incident CRC cases within a large, Norwegian cohort.

Methods

Participants’ weight was measured at health examinations up to three times between 1974 and 1988. CRC cases were identified through linkage with the Norwegian Cancer Registry. In total, 1336 men and 1180 women with a weight measurement >3 years prior to diagnosis were included in analyses. Hazard ratios (HRs) and confidence intervals (CIs) were estimated with Cox regression.

Results

During a mean follow-up of 5.8 years, 507 men and 432 women died from CRC. Obesity (BMI ≥30 kg/m2) was associated with higher CRC-specific mortality than normal weight (BMI 18.5–25 kg/m2) in men with proximal colon cancer, HR = 1.85 (95 % CI 1.08–3.16) and in women with rectal cancer, HR = 1.93 (95 % CI 1.13–3.30). Weight gain was associated with higher CRC-specific mortality in women with CRC, colon cancer, and distal colon cancer, HRs per 5 kg weight gain were 1.18 (95 % CI 1.01–1.37), 1.22 (95 % CI 1.02–1.45), and 1.40 (95 % CI 1.01–1.95), respectively. Weight gain was not significantly associated with survival in men.

Conclusions

Maintaining a healthy weight may benefit CRC survival, at least in women.
Appendix
Available only for authorised users
Literature
1.
World Cancer Research Fund/American Institute for Cancer Research. Systematic literature review. Continuous update project report. The association between food, nutrition and physical activity and the risk of colorectal cancer. 2010.
2.
Robsahm TE, Aagnes B, Hjartåker A, Langseth H, Bray FI, Larsen IK. Body mass index, physical activity, and colorectal cancer by anatomical subsites: a systematic review and meta-analysis of cohort studies. Eur J Cancer Prev. 2013;22:492–505.CrossRefPubMed
3.
4.
5.
Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O’Connell MJ, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647–54.CrossRefPubMed
6.
Hines RB, Shanmugam C, Waterbor JW, McGwin Jr G, Funkhouser E, Coffey CS, et al. Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer. 2009;115:5798–806.CrossRefPubMedPubMedCentral
7.
Sinicrope FA, Foster NR, Sargent DJ, O’Connell MJ, Rankin C. Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010;16:1884–93.CrossRefPubMedPubMedCentral
8.
Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22:648–57.CrossRefPubMed
9.
Ballian N, Yamane B, Leverson G, Harms B, Heise CP, Foley EF, et al. Body mass index does not affect postoperative morbidity and oncologic outcomes of total mesorectal excision for rectal adenocarcinoma. Ann Surg Oncol. 2010;17:1606–13.CrossRefPubMed
10.
Adelstein BA, Macaskill P, Chan SF, Katelaris PH, Irwig L. Most bowel cancer symptoms do not indicate colorectal cancer and polyps: a systematic review. BMC Gastroenterol. 2011;11:65.CrossRefPubMedPubMedCentral
11.
Lee J, Meyerhardt JA, Giovannucci E, Jeon JY. Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies. PLoS One. 2015;10:e0120706.CrossRefPubMedPubMedCentral
12.
Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012;30:42–52.CrossRefPubMed
13.
Boyle T, Fritschi L, Platell C, Heyworth J. Lifestyle factors associated with survival after colorectal cancer diagnosis. Br J Cancer. 2013;109:814–22.CrossRefPubMedPubMedCentral
14.
Fedirko V, Romieu I, Aleksandrova K, Pischon T, Trichopoulos D, Peeters PH, et al. Pre-diagnostic anthropometry and survival after colorectal cancer diagnosis in Western European populations. Int J Cancer. 2014;135:1949–60.CrossRefPubMed
15.
Reichle K, Peter RS, Concin H, Nagel G. Associations of pre-diagnostic body mass index with overall and cancer-specific mortality in a large Austrian cohort. Cancer Causes Control. 2015;26:1643–52.CrossRefPubMed
16.
Maskarinec G, Harmon BE, Little MA, Ollberding NJ, Kolonel LN, Henderson BE, et al. Excess body weight and colorectal cancer survival: the multiethnic cohort. Cancer Causes Control. 2015;26:1709–18.CrossRefPubMedPubMedCentral
17.
Campbell PT, Newton CC, Newcomb PA, Phipps AI, Ahnen DJ, Baron JA, et al. Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype. Cancer Epidemiol Biomarkers Prev. 2015;24:1229–38.CrossRefPubMedPubMedCentral
18.
Haydon AM, MacInnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 2006;55:62–7.CrossRefPubMedPubMedCentral
19.
Doria-Rose VP, Newcomb PA, Morimoto LM, Hampton JM, Trentham-Dietz A. Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States). Cancer Causes Control. 2006;17:63–70.CrossRefPubMed
20.
Prizment AE, Flood A, Anderson KE, Folsom AR. Survival of women with colon cancer in relation to precancer anthropometric characteristics: the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev. 2010;19:2229–37.CrossRefPubMedPubMedCentral
21.
Pelser C, Arem H, Pfeiffer RM, Elena JW, Alfano CM, Hollenbeck AR, et al. Prediagnostic lifestyle factors and survival after colon and rectal cancer diagnosis in the National Institutes of Health (NIH)-AARP Diet and Health Study. Cancer. 2014;120(10):1540–7.CrossRefPubMedPubMedCentral
22.
Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst. 2015;107.
23.
Laake I, Thune I, Selmer R, Tretli S, Slattery ML, Veierød MB. A prospective study of body mass index, weight change, and risk of cancer in the proximal and distal colon. Cancer Epidemiol Biomarkers Prev. 2010;19:1511–22.CrossRefPubMed
24.
Bjartveit K, Foss OP, Gjervig T, Lund-Larsen PG. The cardio vascular disease study in Norwegian counties. Background and organization. Acta Med Scand Suppl. 1979;634:1–70.PubMed
25.
Hsieh FY, Lavori PW. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin Trials. 2000;21:552–60.CrossRefPubMed
26.
World Health Organization. Obesity: Preventing and managing the global epidemic. Report No 894. Geneva: WHO; 2000.
27.
Park SM, Lim MK, Shin SA, Yun YH. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol. 2006;24:5017–24.CrossRefPubMed
28.
Kuiper JG, Phipps AI, Neuhouser ML, Chlebowski RT, Thomson CA, Irwin ML, et al. Recreational physical activity, body mass index, and survival in women with colorectal cancer. Cancer Causes Control. 2012;23:1939–48.CrossRefPubMedPubMedCentral
29.
Slattery ML, French TK, Egger MJ, Lyon JL. Diet and survival of patients with colon cancer in Utah: Is there an association. Int J Epidemiol. 1989;18:792–7.CrossRefPubMed
30.
Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010;46:2788–98.CrossRefPubMed
31.
Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN, McLaughlin JR, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst. 2010;102:391–400.CrossRefPubMedPubMedCentral
32.
Hughes LA, Williamson EJ, Van EM, Jenkins MA, Giles GG, Hopper JL, et al. Body size and risk for colorectal cancers showing BRAF mutations or microsatellite instability: a pooled analysis. Int J Epidemiol. 2012;41:1060–72.CrossRefPubMed
33.
34.
Lovejoy JC, Champagne CM, De JL, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond). 2008;32:949–58.CrossRef
35.
Roberts DL, Dive C, Renehan AG. Biological mechanisms linking obesity and cancer risk: New perspectives. Annu Rev Med. 2010;61:301–16.CrossRefPubMed
36.
Cole SR, Platt RW, Schisterman EF, Chu H, Westreich D, Richardson D, et al. Illustrating bias due to conditioning on a collider. Int J Epidemiol. 2010;39:417–20.CrossRefPubMed
37.
Smits LJ, van Kuijk SM, Leffers P, Peeters LL, Prins MH, Sep SJ. Index event bias-a numerical example. J Clin Epidemiol. 2013;66:192–6.CrossRefPubMed
38.
Wilsgaard T, Jacobsen BK, Schirmer H, Thune I, Løchen ML, Njølstad I, et al. Tracking of cardiovascular risk factors: the Tromsø study, 1979-1995. Am J Epidemiol. 2001;154:418–26.CrossRefPubMed
39.
Ulmer H, Kelleher C, Diem G, Concin H. Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system: the Vorarlberg Health Monitoring & Promotion Programme. Eur Heart J. 2003;24:1004–13.CrossRefPubMed
Metadata
Title
Pre-diagnostic body mass index and weight change in relation to colorectal cancer survival among incident cases from a population-based cohort study
Authors
Ida Laake
Inger K. Larsen
Randi Selmer
Inger Thune
Marit B. Veierød
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2445-4

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model

Research article

INFα-2b inhibitory effects on CD4+CD25+FOXP3+ regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts

Research article

Oral cancer incidence and survival rates in the Republic of Ireland, 1994-2009

Research article

Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [18F]-L-FBPA positron emission tomography in boron neutron capture therapy

Research article

Genetic polymorphisms of FAS and EVER genes in a Greek population and their susceptibility to cervical cancer: a case control study

Case report

Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits